These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 35510091)
81. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection. Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075 [TBL] [Abstract][Full Text] [Related]
82. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection. Whitney L; Nesnas J; Planche T Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306 [TBL] [Abstract][Full Text] [Related]
83. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. Shah DN; Aitken SL; Barragan LF; Bozorgui S; Goddu S; Navarro ME; Xie Y; DuPont HL; Garey KW J Hosp Infect; 2016 Jul; 93(3):286-9. PubMed ID: 27209056 [TBL] [Abstract][Full Text] [Related]
84. Readmission, healthcare consumption, and mortality in Clostridioides difficile infection hospitalizations: a nationwide cohort study. Sharma S; Weissman S; Walradt T; Aziz M; Vohra I; Acharya A; Sotiriadis J; Feuerstein JD; Tabibian JH Int J Colorectal Dis; 2021 Dec; 36(12):2629-2635. PubMed ID: 34363511 [TBL] [Abstract][Full Text] [Related]
85. Health Care Resource Utilization and Costs Among Medicare Beneficiaries Newly Diagnosed With Peripheral T-cell Lymphoma: A Retrospective Claims Analysis. Shah A; Petrilla A; Rebeira M; Feliciano J; Lisano J; LeBlanc TW Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e1-e9. PubMed ID: 33184000 [TBL] [Abstract][Full Text] [Related]
86. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379 [TBL] [Abstract][Full Text] [Related]
88. Cost burden of Clostridioides difficile infection to the health service: A retrospective cohort study in Scotland. Robertson C; Pan J; Kavanagh K; Ford I; McCowan C; Bennie M; Marwick C; Leanord A J Hosp Infect; 2020 Nov; 106(3):554-561. PubMed ID: 32717202 [TBL] [Abstract][Full Text] [Related]
89. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020 [TBL] [Abstract][Full Text] [Related]
90. Outcomes of Patients Who Developed Clostridioides difficile Infection During Hospitalization and Had a History of Comorbid Post-Traumatic Stress Disorder. Patel SJ; Kaye A; Meyers SR; Ahlawat S Cureus; 2022 Sep; 14(9):e28810. PubMed ID: 36225473 [TBL] [Abstract][Full Text] [Related]
91. The burden of Clostridioides difficile infection in patients with history of liver transplant and during index admission. Wijarnpreecha K; Aby ES; Kim D; Ungprasert P; Cheungpasitporn W; Thongprayoon C; Lukens FJ; Harnois DM; Kröner PT Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):894-898. PubMed ID: 32541243 [TBL] [Abstract][Full Text] [Related]
92. Fecal Microbiota Transplant in Severe and Non-Severe Popa D; Neamtu B; Mihalache M; Boicean A; Banciu A; Banciu DD; Moga DFC; Birlutiu V J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945118 [TBL] [Abstract][Full Text] [Related]
93. Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies. Giacobbe DR; Dettori S; Di Bella S; Vena A; Granata G; Luzzati R; Petrosillo N; Bassetti M Infect Dis Ther; 2020 Sep; 9(3):481-494. PubMed ID: 32632582 [TBL] [Abstract][Full Text] [Related]
94. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Ali H; Khurana S; Ma W; Peng Y; Jiang ZD; DuPont H; Zhang HC; Thomas AS; Okhuysen P; Wang Y J Cancer; 2021; 12(21):6498-6506. PubMed ID: 34659541 [No Abstract] [Full Text] [Related]
95. Impact of infectious complications after elective surgery on hospital readmission and late deaths in the U.S. Medicare population. Vogel TR; Dombrovskiy VY; Lowry SF Surg Infect (Larchmt); 2012 Oct; 13(5):307-11. PubMed ID: 23082877 [TBL] [Abstract][Full Text] [Related]
97. First Clostridioides difficile Recurrence Is Highest Following Concomitant Antimicrobial Administration During and Within 30 Days of Treatment. Chaar A; Damianos J; Rizwan R; Al-Nahhas H; Mansoor MS; Sharma P; Malik U; Feuerstadt P Dig Dis Sci; 2023 Nov; 68(11):4221-4229. PubMed ID: 37665427 [TBL] [Abstract][Full Text] [Related]
98. Characteristics of Patients With Initial Guh AY; Li R; Korhonen L; Winston LG; Parker E; Czaja CA; Johnston H; Basiliere E; Meek J; Olson D; Fridkin SK; Wilson LE; Perlmutter R; Holzbauer SM; D'Heilly P; Phipps EC; Flores KG; Dumyati GK; Pierce R; Ocampo VLS; Wilson CD; Watkins JJ; Gerding DN; McDonald LC Open Forum Infect Dis; 2024 Apr; 11(4):ofae127. PubMed ID: 38577028 [TBL] [Abstract][Full Text] [Related]
99. A Systematic Literature Review on Risk Factors for and Timing of Clostridioides difficile Infection in the United States. Eeuwijk J; Ferreira G; Yarzabal JP; Robert-Du Ry van Beest Holle M Infect Dis Ther; 2024 Feb; 13(2):273-298. PubMed ID: 38349594 [TBL] [Abstract][Full Text] [Related]
100. Burden of Medically Attended Diarrhea and Outpatient Tartof SY; Schmidt MA; Contreras R; Angulo FJ; Florea A; Barreras JL; Donald J; Zamparo J; Grant DL; Shuster E; Gonzalez E; Kuntz JL Open Forum Infect Dis; 2024 Jan; 11(1):ofad680. PubMed ID: 38250203 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]